Know Cancer

forgot password

Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies

Phase 1
18 Years
Open (Enrolling)
BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Unspecified Adult Solid Tumor, Protocol Specific

Thank you

Trial Information

Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies


I. Establish the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the
combination of ABT-888 and gemcitabine (gemcitabine hydrochloride) in patients with advanced
solid tumors.


I. Establish the safety and tolerability of the combination of ABT-888 and gemcitabine in
patients with solid tumors.

II. Determine the effects of ABT-888 and gemcitabine treatment on DNA damage response by
analysis of markers such as Ataxia telangiectasia mutated (ATM) in peripheral blood
mononuclear cells (PBMCs).

III. Determine the pharmacokinetics of ABT-888 and gemcitabine when administered in

IV. Determine the generation of gemcitabine triphosphate in PBMCs. V. Document any evidence
of antitumor response.

OUTLINE: This is a dose-escalation study.

Patients receive oral ABT-888 twice daily on days 1-14 and gemcitabine hydrochloride IV over
30 minutes on days 1, 8, and 15. Courses repeat every 21* days in the absence of disease
progression or unacceptable toxicity.

After completion of study therapy, patients are followed up for at least 4 weeks.

NOTE: *Patients previously enrolled on a 4-week schedule (ABT-888 twice daily on days 1-21
with gemcitabine IV over 30 minutes once weekly on days 1, 8, and 15, and courses repeating
every 28 days) will continue on the 4-week schedule.

Inclusion Criteria:

- Histologically confirmed solid tumors meeting 1 of the following criteria:

- Progressive disease following standard therapy

- Disease for which acceptable standard treatment options do not exist

- May have received 0-2 prior chemotherapeutic regimens (single-agent or combination

- Willing to undergo BRCA mutation analysis

- Known BRCA mutations allowed

- All patients, at any dose level, without a known BRCA mutation undergo screening
with the BRCAPRO program to assess the likelihood of having a BRCA mutation

- Patients with a BRCAPRO likelihood of gene mutation of ≥ 20% must undergo BRCA
gene testing by the Myriad Genetic Laboratories in order to participate in the

- Patients are eligible whether they have a known deleterious BRCA 1 or 2
mutation or a mutation of uncertain significance

- No CNS disease (e.g., brain metastases or glioma)

- No active seizure or history of seizure disorder

- ECOG performance status 0-2 (Karnofsky 60-100%)

- Life expectancy > 3 months

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Bilirubin < 2.0 mg/dL

- AST and ALT < 3 times upper limit of normal

- Creatinine normal OR creatinine clearance > 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to swallow pills

- HIV-positive patients allowed provided that CD4 counts are < 500 and not on protease

- No uncontrolled diarrhea

- No uncontrolled intercurrent illness including, but not limited to, any of the

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness or social situations that would limit compliance with study

- No other concurrent anticancer therapies or agents

- More than 4 weeks since prior major surgery, radiotherapy, or chemotherapy (6 weeks
for mitomycin C or nitrosoureas) and recovered

- Prior gemcitabine hydrochloride or PARP inhibition therapy, including ABT-888,

- No prior combination of gemcitabine hydrochloride and any PARP inhibitor

- Concurrent bisphosphonate IV allowed provided treatment was initiated before study
therapy (for patients with bone metastases or hypercalcemia)

- Patients with prostate cancer must continue luteinizing-hormone releasing-hormone
agonist therapy and discontinue antiandrogens (≥ 6 weeks since bicalutamide and ≥ 4
weeks since flutamide)

- No other concurrent investigational agents

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

MTD of ABT-888 and gemcitabine hydrochloride, determined according to incidence of DLT graded using the NCI CTCAE version 4.0

Outcome Time Frame:

3 weeks

Safety Issue:


Principal Investigator

Ronald Stoller

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Pittsburgh


United States: Food and Drug Administration

Study ID:




Start Date:

May 2010

Completion Date:

Related Keywords:

  • brca1 Mutation Carrier
  • brca2 Mutation Carrier
  • Unspecified Adult Solid Tumor, Protocol Specific



University of Pittsburgh Pittsburgh, Pennsylvania  15261
UPMC Hillman Cancer Center Pittsburgh, Pennsylvania  15232
Penn State Milton S Hershey Medical Center Hershey, Pennsylvania  17033
Magee-Womens Hospital - University of Pittsburgh Medical Center Pittsburgh, Pennsylvania  15213